The Phase 1b study by Aligos Therapeutics to assess its Class II Capsid Assembly modulator, ALG-000184, started with a 12-week dosing cohort.
The clinical-stage biopharmaceutical company Aligos Therapeutics, Inc. (Nasdaq:ALGS), which focuses on creating novel treatments for unmet medical needs in viral and liver diseases, announced today that enrollment in a 12-week dosing cohort of HBeAg-positive chronic ... [Read]
Senate Bill Decriminalizing Psychedelics Could Help Reverse Some ‘War on Drugs’ Impacts
The global need for effective mental health treatment has led to the growing push for the legalization of psychedelic therapies, pushing the market into the mainstream. Last week, Michigan Senator Jeff Irwin introduced legislation that ... [Read]
New COVID-19 Vaccine Mandates Make Rapid COVID Tests More Essential Than Ever
With the number of new COVID cases surging, fueled by a highly contagious Delta variant and only 50% of the US population having been vaccinated, rapid COVID tests and treatments are more important than ever. ... [Read]
Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness
The early 1970s saw psychedelics and psilocybin products made illegal in the US in the war on drugs. Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic ... [Read]
Psychedelic Decriminalization Creating Market Opportunities
What was once a war on drugs has turned into a public push for the decriminalization and legalization of illegal drugs with potential therapeutic benefits. Legalization efforts began with marijuana in 2018, creating a booming ... [Read]
Psychedelics Move to The Forefront of Innovative Research as the FDA Approves Large-Scale Testing
Psychedelics are quietly being used in clinical settings on small numbers of patients, but they are moving quickly toward medical approval. The FDA recently approved large-scale human trials to determine whether MDMA and other psychedelics ... [Read]
MNK Stock Tanks on DOJ Suit for Underpayment of Medicaid Rebates
MNK stock is sinking this week after it was reported that the US Department of Justice (DOJ) is suing Mallinckrodt (NYSE:MNK) for alleged underpayment of Medicaid rebates. The embattled pharmaceutical firm, which is currently involved ... [Read]
ASRT Stock Soars 52% on Asset Sale to Collegium for $375 Million
ASRT stock has been on a tearing rally this morning on the back of a significant announcement this morning. Big Development Assertio Therapeutics Inc (NASDAQ:ASRT) made an announcement with regards to a crucial asset sale, ... [Read]
AMRX Stock Soars as FDA Approves EluRyng: Next Steps
When it comes to significant movements in the stock price of a pharmaceutical company, then there are very few triggers that are better than that of positive development with regards to a product in the ... [Read]
MNK Stock Drops as Company Announces Opioid Crisis Oversight Report
MNK stock is trading down on Wednesday after Mallinckrodt (NYSE:MNK) announced plans to publish a report into the board’s oversight of risks related to the company’s role in contributing to the opioid crisis in the ... [Read]